The estimated Net Worth of David Thomson is at least $9.32 Million dollars as of 27 August 2024. David Thomson owns over 5,553 units of Mannkind Corp stock worth over $5,086,938 and over the last 20 years he sold MNKD stock worth over $3,241,858. In addition, he makes $988,410 as Executive Vice President, General Counsel, and Secretary at Mannkind Corp.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
David Thomson MNKD stock SEC Form 4 insiders trading
David has made over 66 trades of the Mannkind Corp stock since 2005, according to the Form 4 filled with the SEC. Most recently he sold 5,553 units of MNKD stock worth $32,985 on 27 August 2024.
The largest trade he's ever made was exercising 150,000 units of Mannkind Corp stock on 11 December 2013 worth over $253,500. On average, David trades about 8,786 units every 59 days since 2004. As of 27 August 2024 he still owns at least 829,843 units of Mannkind Corp stock.
You can see the complete history of David Thomson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Thomson biography
Dr. David B. Thomson Ph.D., J.D. serves as Executive Vice President, General Counsel, Secretary of the Company. Prior to joining us, he practiced corporate/commercial and securities law at a major Toronto law firm. Earlier in his career, Dr. Thomson was a post-doctoral fellow at the Rockefeller University. Dr. Thomson obtained his bachelor’s degree, master’s degree and Ph.D. degree from Queens University and obtained his J.D. degree from the University of Toronto.
What is the salary of David Thomson?
As the Executive Vice President, General Counsel, and Secretary of Mannkind Corp, the total compensation of David Thomson at Mannkind Corp is $988,410. There are 3 executives at Mannkind Corp getting paid more, with Michael Castagna having the highest compensation of $1,551,760.
How old is David Thomson?
David Thomson is 53, he's been the Executive Vice President, General Counsel, and Secretary of Mannkind Corp since 2002. There are 15 older and 6 younger executives at Mannkind Corp. The oldest executive at Mannkind Corp is Kent Kresa, 82, who is the Independent Chairman of the Board.
What's David Thomson's mailing address?
David's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.
Insiders trading at Mannkind Corp
Over the last 20 years, insiders at Mannkind Corp have traded over $14,187,027 worth of Mannkind Corp stock and bought 107,212,962 units worth $2,707,661,837 . The most active insiders traders include Alfred E Mann, Juergen Martens, and David Thomson. On average, Mannkind Corp executives and independent directors trade stock every 27 days with the average trade being worth of $3,220,647. The most recent stock trade was executed by Stuart A Tross on 3 September 2024, trading 25,000 units of MNKD stock currently worth $156,500.
What does Mannkind Corp do?
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
What does Mannkind Corp's logo look like?
Complete history of David Thomson stock trades at Mannkind Corp
Mannkind Corp executives and stock owners
Mannkind Corp executives and other stock owners filed with the SEC include:
-
Michael Castagna,
Chief Executive Officer, Director -
Dr. Michael E. Castagna Pharm.D.,
CEO & Director -
Stuart Tross,
Chief People and Workplace Officer -
David Thomson,
Executive Vice President, General Counsel, Secretary -
Dr. Michael E. Castagna,
CEO & Director -
Steven Binder,
Chief Financial Officer -
Dr. David B. Thomson,
Exec. VP, Gen. Counsel & Sec. -
Joseph Kocinsky,
Chief Technology Officer -
Steven B. Binder,
Chief Financial Officer -
Joseph Kocinsky M.B.A., M.S.,
Chief Technology Officer -
Dr. Stuart A. Tross,
Chief People & Workplace Officer -
Rosabel Alinaya,
Vice President of Investor Relations, Interim Corporate Controller, Treasurer -
Christine Mundkur,
Independent Director -
Kent Kresa,
Independent Chairman of the Board -
Ronald Consiglio,
Independent Director -
Michael Friedman,
Independent Director -
James Shannon,
Independent Director -
Kevin Kaiserman,
Vice President - Medical Affairs and Safety -
Jennifer Grancio,
Independent Director -
Anthony Hooper,
Independent Director -
Alejandro Galindo M.B.A., M.S.,
Chief Commercial Officer -
James Patrick McCauley Jr., J.D., M.B.A.,
Chief Commercial Officer -
John F. Bedard,
Sr. VP of Worldwide Regulatory Affairs -
Rosabel Realica Alinaya,
VP of Investor Relations & Treasury -
Thomas Hofmann M.D., Ph.D.,
Chief Scientific Officer -
Matthew J Pfeffer,
Corporate VP and CFO -
Henry L Nordhoff,
Director -
David Mac Callum,
Director -
Raymond W. Urbanski,
Corp VP, CMO -
David M Kendall,
Chief Medical Officer -
Elizabeth Garrett Ingram,
Chief Marketing Officer -
Courtney Barton,
Chief Compl & Privacy Officer -
Patrick Mc Cauley,
Chief Commercial Officer -
John R. Riesenberger,
VP & Chief Commercial Officer -
Richard L Anderson,
VP & CFO -
Heather Hay Murren,
Director -
Kathleen Connell,
Director -
Llew Keltner,
Director -
Dan Burns,
VP & President, MKBP -
W Wendell Cheatham,
VP, Medical & Reg Affairs -
Juergen Martens,
Corporate VP -
Hakan Edstrom,
President & COO -
Alfred E Mann,
Chairman & CEO -
Diane Palumbo,
Vice President, Human Resource -
Abraham E Cohen,
Director -
Peter C Richardson,
Chief Scientific Officer -
Lauren M Sabella,
EVP Chief Operating Officer -
Alejandro Galindo,
EVP Endocrine Business Unit -
Burkhard Blank,
EVP Chief Medical Officer -
Sanjay R Singh,
EVP Technical Operations -
Christopher B Prentiss,
Chief Financial Officer -
Sabrina Kay,